Adult Clinical Trials

Melanoma and other skin cancers

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Melanoma Clinical Trials Office at 919.684.8239.

8 trials identified.

AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, PHASE 1B/2 STUDY OF THE SAFETY, EFFICACY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF RTA 408 IN COMBINATION WITH IPILIMUMAB OR NIVOLUMAB IN THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: April Salama
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00059068
View this trial at ClinicalTrials.gov

Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Brent Hanks
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00059349

A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody -Drug Conjugate, as Monotherapy or in Combination with Immunotherapies in Patients with Advanced Melanoma
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: April Salama
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00065547
View this trial at ClinicalTrials.gov

A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melanoma
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: April Salama
Contact: Melanoma Clinical Trials Research Office
Phone: 919 .613.0400
Reference Number: 00067271
View this trial at ClinicalTrials.gov

A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Dan Blazer
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00069107
View this trial at ClinicalTrials.gov

A Phase lb/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of lntratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Protocol DV3-MEL-01)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: April Salama
Contact: MELANOMA CLINICAL TRIALS RESEARCH OFFICE
Phone: 919.613.0400
Reference Number: 00074136
View this trial at ClinicalTrials.gov

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: April Salama
Contact: MELANOMA ONCOLOGY CLINICAL TRIALS OFFICE
Phone: 919.613.0400
Reference Number: 00082289
View this trial at ClinicalTrials.gov

A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: April Salama
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00082290
View this trial at ClinicalTrials.gov